News
There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...
6don MSN
The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...
Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...
The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.
Novavax Inc. shares fell after the Wall Street Journal reported that US regulators asked the company to conduct another ...
A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...
Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...
1dOpinion
MedPage Today on MSNInside the FDA: Low Morale and Uncertainty Plague StaffSeveral current and former FDA employees who spoke to Inside Medicine on the condition of anonymity have come to see the ...
Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...
The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.
Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...
WASHINGTON (AP) — The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results